Close
Biotechgate
| |

Home Page

News in the Life Sciences Industry

Results 21 - 40 out of 500 displayed.
«  1 2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 »
Reset 

Tresiba® demonstrated significantly improved blood sugar control and lower rates of hypoglycaemia versus insulin glargine U300 in real-world evidence study

Read more ››
By: Nasdaq / GlobenewsWire - 23 Jun 2018

Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA)

Read more ››
By: Nasdaq / GlobenewsWire - 23 Jun 2018

Ozempic® provided greater weight reductions for adults with a baseline BMI of or above 25 kg/m2 than those with lower baseline BMI <25 kg/m2, in a SUSTAIN 7 post-hoc analysis

Read more ››
By: Nasdaq / GlobenewsWire - 23 Jun 2018

Significant Blood Sugar Improvement With Xultophy(R) Compared to Insulin Glargine U-100 When Used as Add-On to Oral Diabetes Medications

BAGSVAERD, Denmark, June 23, 2018 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 23 Jun 2018

Ozempic® Provided Greater Weight Reductions for Adults With a Baseline BMI >=25kg/m2 Than Those With Lower Baseline BMI <25kg/m2, in a SUSTAIN 7 Post-hoc Analysis

ORLANDO, Florida, June 23, 2018 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 23 Jun 2018

Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO 20th World Congress on Gastrointestinal Cance

BOULDER, Colo., June 23, 2018 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK... Read more ››

By: PR Newswire Association LLC. - 23 Jun 2018
Related companies:  Array BioPharma Inc.

New Data Show Amgen's Repatha® (evolocumab) Significantly Reduced LDL-C And Non-HDL-C In High-risk Patients With Type 2 Diabetes

THOUSAND OAKS, Calif., June 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data that show Repatha(®) (evolocumab) significantly reduced low-density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) in patients with Type 2 diabetes and... Read more ››

By: PR Newswire Association LLC. - 23 Jun 2018
Related companies:  AMGEN, INC.

Two-year Data from ViaCyte's STEP ONE Clinical Trial Presented at ADA 2018

SAN DIEGO, June 23, 2018 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, today announced two-year data from Cohort 1 of the ongoing Safety, Tolerability, and Efficacy of VC-01(TM) (PEC-Encap(TM))... Read more ››

By: PR Newswire Association LLC. - 23 Jun 2018
Related companies:  ViaCyte, Inc.

Investigational Doses of Lilly's Once-Weekly Trulicity® (dulaglutide) Show Promise in Delivering Powerful Efficacy in People with Type 2 Diabetes

INDIANAPOLIS, June 23, 2018 /PRNewswire/ -- Two investigational doses of Lilly's dulaglutide (4.5 mg and 3.0 mg), as well as Trulicity(®) (dulaglutide) 1.5 mg, provided significantly better blood sugar control with weight benefits compared to placebo in adults with type 2 diabetes.(1) Data from... Read more ››

By: PR Newswire Association LLC. - 23 Jun 2018
Related companies:  Eli Lilly and Company

Significant blood sugar improvement with Xultophy® 100/3.6 compared to insulin glargine U-100 when used as add-on to oral diabetes medications

ORLANDO, Fla., June 23, 2018 /PRNewswire/ -- Xultophy(®) 100/3.6 (insulin degludec and liraglutide injection) 100 units/mL and 3.6 mg/mL provided superior A1C reduction compared to insulin glargine U-100 (1.94% vs 1.68% respectively; p?0.0001) when used as an add-on to a SGLT-2i (an oral diabetes... Read more ››

By: PR Newswire Association LLC. - 23 Jun 2018
Related companies:  Novo Nordisk Inc.

Gaumard's Growing Family Takes Center Stage at AWHONN '18

MIAMI, June 23, 2018 /PRNewswire/ -- With women's health, obstetric and neonatal nurses taking on ever-greater responsibilities, there's no better time than AWHONN's 2018 annual convention, from today through June 27 in Tampa, to see Gaumard's... Read more ››

By: PR Newswire Association LLC. - 23 Jun 2018
Related companies:  Gaumard Scientific

Real-World Evidence Shows Oral INVOKANA® (canagliflozin) Results in Greater Weight Loss and Treatment Adherence Than Injectable GLP-1 Receptor Agonists in Type 2 Diabetes Patients

TITUSVILLE, N.J. and ORLANDO, Fla., June 23, 2018 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new findings from two real-world studies comparing sodium glucose co-transporter-2 inhibitor (SGLT2i) INVOKANA(®) (canagliflozin) and glucagon-like... Read more ››

By: PR Newswire Association LLC. - 23 Jun 2018

Fractyl Announces Presentation of Key Scientific Research at ADA 2018 Indicating That Modern Diets Durably Alter Duodenal Lining, Highlighting the Intestine's Role in Type 2 Diabetes and NASH

LEXINGTON, Mass. and ORLANDO, Fla., June 23, 2018 /PRNewswire/ -- Fractyl Laboratories Inc. (Fractyl) today announced the presentation of breakthrough research providing the first clear mechanistic link between modern diets and their... Read more ››

By: PR Newswire Association LLC. - 23 Jun 2018
Related companies:  Fractyl Laboratories, Inc.

New Data Presented at the American Diabetes Association 78th Scientific Sessions® Reinforce Potential of Lilly's Ultra Rapid Lispro in People with Type 1 and Type 2 Diabetes

INDIANAPOLIS, June 23, 2018 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) ultra rapid lispro (URLi) led to improved and sustained blood sugar control after meals in people with type 1 and type 2 diabetes, according to results from three phase 1b studies evaluating URLi compared to Humalog(®).... Read more ››

By: PR Newswire Association LLC. - 23 Jun 2018
Related companies:  Eli Lilly and Company

Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors

RIDGEFIELD, Conn. and INDIANAPOLIS, June 23, 2018 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced findings from two new analyses of the landmark EMPA-REG OUTCOME(®) trial, presented at the 78(th) American Diabetes Association (ADA) Scientific Sessions(®).... Read more ››

By: PR Newswire Association LLC. - 23 Jun 2018
Related companies:  Eli Lilly and Company

Oral Semaglutide Demonstrated Significant Reduction in Blood Sugar vs Placebo in PIONEER 1 Trial

ORLANDO, Florida, June 23, 2018 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 23 Jun 2018
Related companies:  Novo Nordisk Inc.

Artificial Intelligence-Powered Sugar.IQ(TM) Diabetes Management App Developed by Medtronic and IBM Watson Health Now Commercially Available

Read more ››
By: Nasdaq / GlobenewsWire - 23 Jun 2018

TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007

Read more ››
By: Nasdaq / GlobenewsWire - 22 Jun 2018

DBV Technologies Announces Results of its 2018 Ordinary and Extraordinary General Meeting and the Appointment of Joan Schmidt as Executive Vice President, General Counsel

Read more ››
By: Nasdaq / GlobenewsWire - 22 Jun 2018

Imagin Provides Further Detail on Kilmer Lucas Engagement

Read more ››
By: Nasdaq / GlobenewsWire - 22 Jun 2018
«  1 2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 »
to the top ↑